{"gene":"PDE4B","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2005,"finding":"DISC1 physically interacts with the UCR2 domain of PDE4B, sequestering it in resting cells; elevation of cellular cAMP causes dissociation of PDE4B from DISC1 and an increase in PDE4B enzymatic activity.","method":"Co-immunoprecipitation, domain-mapping, cellular cAMP elevation assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal interaction mapped to UCR2 domain, functional consequence (activity change) demonstrated, widely replicated by subsequent studies","pmids":["16293762"],"is_preprint":false},{"year":2002,"finding":"PDE4B (but not PDE4D) is required for LPS-induced TNF-alpha production in peripheral leukocytes and macrophages; LPS stimulation induces PDE4B mRNA accumulation and increases PDE4 enzymatic activity, constituting a feedback regulation essential for the innate immune response.","method":"PDE4B knockout mice, LPS stimulation, cytokine measurement (TNF-alpha mRNA and protein), PDE4 activity assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with specific phenotypic readout, multiple cell types tested, multiple orthogonal methods (mRNA, protein, enzyme activity)","pmids":["12032334"],"is_preprint":false},{"year":1997,"finding":"Three human PDE4B splice variants (HSPDE4B1, HSPDE4B2, HSPDE4B3) differ in their unique N-terminal regions, subcellular distribution (cytosol vs. particulate fractions), maximal cAMP hydrolytic activity, and sensitivity to rolipram inhibition; the N-terminal splice region determines these isoform-specific properties.","method":"Molecular cloning, transient expression in COS7 cells, subcellular fractionation, cAMP hydrolysis assay, rolipram inhibition assay","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic reconstitution with isoform comparisons, fractionation, and inhibitor assays in a single rigorous study","pmids":["9371714"],"is_preprint":false},{"year":2004,"finding":"PDE4B inactivates cAMP to abrogate cAMP-induced apoptosis in diffuse large B-cell lymphoma (DLBCL); this cAMP-mediated apoptosis is largely independent of PKA and EPAC but associated with inhibition of the PI3K/AKT pathway, with AKT centrally required as confirmed by constitutively active AKT mutants.","method":"DLBCL cell lines reconstituted with wild-type or mutant PDE4B, cAMP-induced apoptosis assay, PI3K/AKT pathway analysis, constitutively active AKT mutant expression","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reconstitution with wild-type and mutant PDE4B, epistasis via constitutively active AKT, multiple orthogonal methods in one study","pmids":["15331441"],"is_preprint":false},{"year":2008,"finding":"DISC1, NDE1, NDEL1, LIS1, and dynein associate with PDE4B and PDE4D within cells; this complex localizes to the centrosome and to synapses in cultured neurons. NDE1 is phosphorylated by PKA whose activity is regulated by PDE4-mediated cAMP hydrolysis, suggesting DISC1 acts as a scaffold assembling these proteins.","method":"Co-immunoprecipitation, immunofluorescence localization in cultured neurons","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP and direct localization, single lab, mechanistic interpretation partially inferred","pmids":["18983980"],"is_preprint":false},{"year":2011,"finding":"PDE4B controls cAMP specifically in a near-membrane subdomain in mouse embryonic fibroblasts; PDE4B ablation increases basal and hormone-dependent cAMP near the plasma membrane but not in bulk cytosol, and selectively affects Toll-like receptor signaling but not CREB-mediated transcription.","method":"PDE4B/PDE4D gene ablation in mouse embryonic fibroblasts, subcellular cAMP reporter assays (FRET-based), phosphoprotein analysis, transcription reporter assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic ablation with subcellular FRET-based cAMP measurement, multiple orthogonal readouts showing compartment-specific function","pmids":["21288894"],"is_preprint":false},{"year":2009,"finding":"Co-crystal structure of a tetrahydrobenzothiophene (THBT) inhibitor with PDE4B revealed an unprecedented binding mode in which the ligand displaces the invariant Gln-443 residue and shifts helix-15 by 1-2 Å; C-terminal residues previously proposed to confer subtype selectivity are resolved and extend into the ligand binding site.","method":"X-ray co-crystal structure determination","journal":"Bioorganic & medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional binding mode, novel structural finding, single study","pmids":["19525117"],"is_preprint":false},{"year":2014,"finding":"High-resolution co-crystal structure of triazine PDE4B inhibitors shows that they interact with both the catalytic domain and a C-terminal regulatory helix (CR3), locking the enzyme in an inactive 'closed' conformation; this provides a structural basis for PDE4B-selective inhibitor design.","method":"X-ray co-crystal structure determination, structure-activity relationship analysis","journal":"Bioorganic & medicinal chemistry letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with defined inactive conformation mechanism, single study with SAR support","pmids":["24998378"],"is_preprint":false},{"year":2013,"finding":"Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD; PDE4B negatively regulates CYLD via specific activation of JNK2 (but not JNK1); in CYLD-deficient mice, PDE4B inhibition no longer suppresses inflammation.","method":"PDE4 inhibitor treatment, CYLD expression assay, JNK1/JNK2 selective activation, CYLD-knockout mice","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (CYLD KO), pathway dissection (JNK1 vs JNK2), multiple orthogonal methods including in vivo validation","pmids":["23575688"],"is_preprint":false},{"year":2015,"finding":"Roflumilast synergizes with NTHi to up-regulate PDE4B2 expression via a PKA catalytic subunit β (PKA-Cβ) / NF-κB p65 cross-talk; PKA-Cβ phosphorylates p65 in a cAMP-dependent manner at Ser276, which is critical for synergistic PDE4B2 induction; up-regulated PDE4B2 contributes to chemokine induction in both enzymatic activity-dependent and -independent manners.","method":"In vitro and in vivo gene expression studies, PKA-Cβ and p65 knockdown/overexpression, site-directed mutagenesis (Ser276), promoter assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mutagenesis, pathway epistasis (PKA-Cβ knockdown), in vitro and in vivo confirmation, single lab with multiple methods","pmids":["25831493"],"is_preprint":false},{"year":2017,"finding":"Smurf2 (E3 ubiquitin ligase) interacts with PDE4B and facilitates its ubiquitination-dependent degradation, thereby activating the cAMP-PKA-CREB pathway; elevated cAMP increases miR-132 expression, which targets CTGF to suppress liver fibrosis.","method":"Co-immunoprecipitation, overexpression/knockdown in transgenic mice, miRNA array, dual-luciferase assay, western blot","journal":"Biochimica et biophysica acta. Molecular cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP interaction, in vivo transgenic model, miRNA target validation; single lab","pmids":["29100790"],"is_preprint":false},{"year":2025,"finding":"CircDlg1 (a circular RNA) forms a ternary complex with PDE4B and Smurf2, blocking Smurf2-mediated ubiquitination and degradation of PDE4B via PDE4B's unique N-terminal targeting domain; elevated PDE4B reduces cAMP and suppresses PKA/CREB anti-inflammatory signaling in microglia.","method":"RNA pulldown, mass spectrometry, RNA immunoprecipitation, co-immunoprecipitation, AAV-mediated knockdown in APP/PS1 mice, behavioral testing","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, pulldown, domain mapping, in vivo validation; single lab","pmids":["40093898"],"is_preprint":false},{"year":2020,"finding":"PDE4B mediates neutrophil-endothelial cell interaction in myocardial ischemia-reperfusion (MI/R) injury via PKA-dependent expression of cell adhesion molecules, promotes neutrophil cardiac infiltration, and promotes coronary microcirculatory obstruction and vascular permeability; PDE4B blockade increases flow-mediated vasodilatation in a PKA- and nitric oxide-dependent manner.","method":"PDE4B knockout mice, bone marrow transplant (cell-specific rescue), coronary artery ligation/reperfusion model, laser Doppler flow, patch-clamp, vasomotor reactivity assays in mouse and human coronary arteries","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with bone marrow chimera for cell-type dissection, human tissue validation, multiple orthogonal functional readouts","pmids":["35899614"],"is_preprint":false},{"year":2020,"finding":"Cardiac overexpression of PDE4B blunts beta-adrenergic receptor stimulation of cAMP, PKA activity, L-type Ca2+ current, Ca2+ transients, and cell contraction; moderate PDE4B overexpression protects against isoproterenol- and pressure overload-induced systolic dysfunction, hypertrophy, fibrosis, and apoptosis.","method":"Transgenic mouse lines with cardiomyocyte-specific PDE4B overexpression, AAV9-PDE4B gene delivery, echocardiography, FRET-based cAMP and PKA imaging, whole-cell patch-clamp, isoproterenol infusion and transverse aortic constriction models","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple transgenic lines, AAV gene therapy model, FRET cAMP imaging, patch-clamp, multiple disease models, multiple orthogonal methods","pmids":["32264695"],"is_preprint":false},{"year":2011,"finding":"PDE4B and GSK-3 both bind the N-terminal region of DISC1 and can converge signals via DISC1 simultaneously; DISC1 Q31L mutation reduces PDE4B binding and increases GSK-3 enzymatic activity, demonstrating that DISC1 genetic variation influences the biochemical complex with PDE4B and GSK-3.","method":"Double-mutant DISC1 mouse models (Q31L and L100P), biochemical analysis of GSK-3 activity and DISC1 binding, pharmacological epistasis (rolipram + TDZD-8)","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with DISC1 mutant mice, biochemical interaction analysis, pharmacological synergy; single lab","pmids":["21376063"],"is_preprint":false},{"year":2011,"finding":"PDE4B knockout mice display enhanced long-term depression (LTD) and increased basal postsynaptic responses in hippocampal slices, but no change in LTP; behaviorally, PDE4B-/- mice show impaired reversal learning in the Morris water maze but normal spatial memory acquisition.","method":"PDE4B knockout mice, hippocampal slice electrophysiology (LTP/LTD protocols), Morris water maze","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with electrophysiology and behavioral readouts, single lab","pmids":["21458469"],"is_preprint":false},{"year":2008,"finding":"PDE4B knockout mice show decreased striatal dopamine and serotonin levels, decreased prepulse inhibition (PPI), decreased baseline locomotor activity, and an exaggerated locomotor response to high-dose amphetamine; PDE4B is required for normal PDE4 catalytic activity in multiple brain regions.","method":"PDE4B knockout mice, monoamine measurement, PPI assay, locomotor activity, amphetamine challenge","journal":"Psychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with neurochemical and behavioral phenotyping, single lab, multiple readouts","pmids":["18060387"],"is_preprint":false},{"year":2007,"finding":"PDE4B mediates at least part of the antipsychotic-like effects of rolipram: rolipram suppresses conditioned avoidance responding (CAR) in wild-type mice but with a 3-fold shift in ED50 in PDE4B knockout mice, demonstrating PDE4B involvement in rolipram's mechanism of action.","method":"PDE4B knockout mice, conditioned avoidance responding assay, rolipram dose-response","journal":"Psychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO pharmacological epistasis, single lab","pmids":["17333137"],"is_preprint":false},{"year":2016,"finding":"PDE4B drives both acute local inflammatory response and chronic systemic inflammatory response after spinal cord injury; Pde4b deletion reduces markers of ER stress and inflammation at the injury site, increases oligodendrocyte mRNA expression, improves white matter sparing, and prevents SCI-induced gut dysbiosis and endotoxemia.","method":"Pde4b knockout mice, thoracic contusion SCI model, molecular markers (GFAP, CD11b, Iba1, Cox2), gut microbiome analysis, locomotor recovery assessment","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with multiple molecular and functional readouts, single lab","pmids":["30557659"],"is_preprint":false},{"year":2016,"finding":"Alcohol feeding increases hepatic PDE4B expression, reduces cAMP levels, and impairs fatty acid oxidation via reduced Cpt1a expression through the Pparα/Sirt1/Pgc1α pathway; Pde4b knockout prevents alcohol-induced hepatic steatosis.","method":"Pde4b knockout mice, alcohol liquid diet feeding, hepatic cAMP measurement, gene expression analysis (Cpt1a, Pparα, Sirt1, Pgc1α), rolipram treatment","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with pharmacological validation, pathway analysis, single lab","pmids":["27287961"],"is_preprint":false},{"year":2022,"finding":"PDE4B is the primary phosphodiesterase expressed in dendritic cells (DCs) and acts as a homeostatic regulator of cAMP: its expression falls when cAMP decreases and rises when cAMP increases, in a PKA-dependent feedback manner.","method":"Gαs-depleted DC mouse model, PDE4B expression analysis, PKA inhibitor experiments, PDE4B inhibitor treatment with T cell response readout","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic Gαs depletion model, pharmacological validation, single lab with multiple readouts","pmids":["35387344"],"is_preprint":false},{"year":2013,"finding":"MYC and PDE4B mutually reinforce each other's expression in a feed-forward loop in B-cell lymphoma; combined targeting of Myc and PDE4 synergistically prevents B lymphoma cell proliferation and survival in vitro and in vivo.","method":"B-lymphoma cell lines, Eμ-myc transgenic mice, co-inhibition experiments, xenograft model, western blot for Myc/PDE4B expression","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic transgenic model, in vivo xenograft, multiple cell line validation; single lab","pmids":["31138843"],"is_preprint":false},{"year":2013,"finding":"IL-2 activates STAT5, which binds the PDE4B gene locus to transcriptionally induce PDE4B expression in activated human PBMCs; PDE4B is expressed in CD8+ but not CD4+ primary T cells, while lymphoid cancer CD4+ cells aberrantly express PDE4B.","method":"Affymetrix microarray, ChIP-on-chip STAT5 cistrome mapping, qRT-PCR validation in PHA-activated human PBMCs, protein expression analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and gene expression validation with orthogonal methods; single lab","pmids":["23451206"],"is_preprint":false},{"year":2018,"finding":"PDE4B deficiency (Pde4b-/-) prevents SCI-induced gut dysbiosis, bacterial overgrowth, and endotoxemia, suggesting PDE4B links gut-CNS inflammation after spinal cord injury.","method":"Pde4b knockout mice, thoracic contusion SCI model, gut microbiome sequencing, endotoxin measurement","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with microbiome and endotoxin readouts, single lab","pmids":["30557659"],"is_preprint":false},{"year":2021,"finding":"PDE4B loss-of-function in sclera decreases cAMP and reduces collagen synthesis, leading to thinner collagen fibrils and myopia progression; inhibition of PDE4 with rolipram inhibits TGF-β2-induced collagen synthesis in human scleral fibroblasts.","method":"Pde4b knockout mice, form deprivation myopia model, scleral transcriptome sequencing, subconjunctival rolipram injection, electron microscopy of collagen fibrils, human scleral fibroblast culture","journal":"Experimental eye research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with in vivo myopia model and in vitro fibroblast validation; single lab","pmids":["34506801"],"is_preprint":false},{"year":2022,"finding":"JDP2 (transcription factor c-Jun dimerization protein 2) directly binds the PDE4B promoter and transcriptionally activates PDE4B expression in hypoxia/reoxygenation-injured cardiomyocytes; JDP2-driven PDE4B upregulation contributes to oxidative stress and apoptosis.","method":"Dual luciferase reporter assay, chromatin immunoprecipitation, siRNA knockdown, overexpression in H9c2 cardiomyocytes under H/R conditions","journal":"Experimental and therapeutic medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase reporter confirm direct transcriptional regulation; single lab","pmids":["35401806"],"is_preprint":false},{"year":2025,"finding":"Acute stress reduces Pde4b-regulated cAMP signaling in auditory GABAergic neurons projecting to somatosensory cortex Sst neurons (AUDGABA-S1TrSst circuit), leading to decreased S1TrSst neuron activity and anxiety-like behavior; targeted Pde4b knockdown in S1TrSst projections mimics this anxiety.","method":"Single-cell sequencing, spatial transcriptome sequencing, targeted Pde4b protein knockdown, optogenetics/chemogenetics of S1TrSst neurons, behavioral tests","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — circuit-specific protein knockdown with behavioral and electrophysiological readouts; single lab","pmids":["39891910"],"is_preprint":false},{"year":2024,"finding":"A hypomorphic PDE4B mutation (Y358C) that decreases cAMP hydrolytic activity prevents spatial memory deficits and brain metabolism impairments in the AppNL-G-F Alzheimer's disease mouse model without reducing amyloid plaque burden; transcriptomic analysis identified Ide, Btaf1, Padi2, and C1qb as differentially expressed genes relevant to this protective effect.","method":"AppNL-G-F knock-in mice crossed with Pde4bY358C hypomorphic mice, Barnes maze, 14C-2-deoxyglucose autoradiography, RNA sequencing","journal":"Neuropsychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic hypomorphic model with multiple functional readouts and transcriptomics; single lab","pmids":["38521860"],"is_preprint":false},{"year":2024,"finding":"PDE4B missense variant M220T (rs775201287) attenuates the PDE4B1 response to forskolin-elicited cAMP elevation in HEK-293 cells, and homozygous Pde4b M220T mice show increased BDNF expression, startle hyperreactivity, PPI deficits, altered fear conditioning, and enhanced persistence of traumatic memories consistent with PTSD-relevant phenotypes.","method":"HEK-293 cell cAMP assay with PDE4B1-M220T, homozygous knock-in mice, behavioral battery, cAMP pathway analysis","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro enzymatic function of variant plus knock-in mouse behavioral phenotyping; single lab","pmids":["39256048"],"is_preprint":false},{"year":2017,"finding":"Attenuation of PDE4B1 activity (via D564A dominant-negative transgene in hippocampus/forebrain) increases CREB and ERK1/2 phosphorylation, enhances hippocampal neurogenesis, increases baseline synaptic transmission, and enhances LTP in male mice.","method":"PDE4B1-D564A dominant-negative transgenic mice, immunoblot for phospho-CREB/ERK, neurogenesis assay, hippocampal electrophysiology (LTP)","journal":"BMC neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-selective dominant-negative approach with electrophysiology and biochemical validation; single lab","pmids":["29197324"],"is_preprint":false},{"year":2012,"finding":"ZNF804a directly binds chromatin proximal to the promoter regions of PRSS16 and COMT, and its expression significantly decreases PDE4B transcript levels, indicating ZNF804a transcriptionally regulates PDE4B expression.","method":"ChIP assay, ZNF804a overexpression, qRT-PCR in neural progenitor cells","journal":"PloS one","confidence":"Low","confidence_rationale":"Tier 3 / Moderate — ChIP shown for PRSS16/COMT but not directly for PDE4B; PDE4B regulation inferred from transcript changes without direct binding evidence","pmids":["22384243"],"is_preprint":false},{"year":2005,"finding":"During late-LTP induction in hippocampal slices, PDE4B protein changes are detected within the PSD-enriched fraction but FISH shows no translocation of PDE4B3 mRNA from soma, suggesting local post-translational modulation or protein translocation to activated synaptic structures regulates cAMP at synapses.","method":"Hippocampal slice LTP recording, subcellular fractionation, FISH, fluorescence imaging","journal":"Brain research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — fractionation with electrophysiology, single lab, mechanistic interpretation is inferential","pmids":["15829230"],"is_preprint":false},{"year":2021,"finding":"NFATc2 activation is required for LPS-induced transcription of PDE4b in macrophages; PDE4b expression peaks at time of peak lung injury then falls during resolution; inhibition of PDE4 activity at peak injury increases cAMP in alveolar macrophages and augments their reparative reprogramming from recruited monocytes.","method":"RNA-seq of flow-sorted macrophages, NFATc2 inhibition assay, intratracheal rolipram, conditional monocyte depletion, adoptive transfer of rolipram-educated macrophages, LysM-GFP mice","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq, transcription factor requirement, adoptive transfer, monocyte depletion epistasis; single lab","pmids":["34318714"],"is_preprint":false},{"year":2025,"finding":"PDE4B overexpression in nucleus pulposus cells upregulates ferroptosis markers (ACSL4, TFRC) and downregulates Nrf2, promoting ferroptosis and IDD pathogenesis; PDE4 inhibitor roflumilast reverses this process, with synergistic effect when combined with ferroptosis inhibitor.","method":"PDE4B overexpression in nucleus pulposus cells, in vivo rat IDD model, PDE4 inhibitor treatment, ferroptosis marker analysis","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, overexpression/inhibitor approach, pathway inference from marker expression","pmids":["39893206"],"is_preprint":false}],"current_model":"PDE4B is a cAMP-specific phosphodiesterase that hydrolyzes cAMP to regulate intracellular signaling: it is physically sequestered by DISC1 via the UCR2 domain in resting cells and released in an activated state upon cAMP elevation; it controls cAMP selectively in near-membrane subcellular compartments; it is transcriptionally induced by LPS (via NF-κB/PKA-Cβ cross-talk) and by IL-2/STAT5 as a feedback regulator of innate and adaptive immunity; it is degraded via Smurf2-mediated ubiquitination (protected by circDlg1); its isoform-specific activity and rolipram sensitivity are determined by alternatively spliced N-terminal regions; and it plays established roles in cardiac beta-adrenergic signaling, neuroinflammation, lymphoma survival (through a Myc-PDE4B feed-forward loop and PI3K/AKT-linked apoptosis resistance), and synaptic plasticity (LTD enhancement in hippocampus)."},"narrative":{"mechanistic_narrative":"PDE4B is a cAMP-specific phosphodiesterase that hydrolyzes cAMP to shape spatially restricted cAMP/PKA signaling and thereby controls innate and adaptive immunity, cardiac beta-adrenergic responses, and synaptic plasticity [PMID:21288894, PMID:12032334, PMID:32264695, PMID:21458469]. Its three human splice variants differ in their unique N-terminal regions, which dictate cytosolic versus particulate distribution, maximal hydrolytic activity, and rolipram sensitivity [PMID:9371714]. Functionally, PDE4B governs cAMP within a near-membrane subdomain rather than the bulk cytosol, selectively gating Toll-like receptor signaling while sparing CREB-mediated transcription [PMID:21288894]. In resting cells PDE4B is sequestered through binding of its UCR2 domain to the scaffold DISC1, from which it is released and activated upon cAMP elevation; DISC1 organizes PDE4B together with NDE1, NDEL1, LIS1, and dynein at the centrosome and synapses, coupling local cAMP hydrolysis to PKA-dependent NDE1 phosphorylation [PMID:16293762, PMID:18983980]. Co-crystal structures define how selective inhibitors act, either by displacing the invariant Gln-443 and shifting helix-15 or by engaging a C-terminal regulatory helix (CR3) to lock the enzyme in a closed, inactive conformation [PMID:19525117, PMID:24998378]. In immunity, PDE4B is required for LPS-induced TNF-alpha production and is transcriptionally induced as a feedback regulator by LPS via PKA-Cbeta/NF-kappaB p65 (Ser276) cross-talk and by IL-2/STAT5, with inhibition suppressing inflammation through JNK2-dependent induction of the deubiquitinase CYLD [PMID:12032334, PMID:25831493, PMID:23451206, PMID:23575688]. PDE4B protein levels are controlled by Smurf2-mediated ubiquitination and degradation, which is blocked by the circular RNA circDlg1 acting through PDE4B's N-terminal targeting domain to maintain low cAMP and dampen anti-inflammatory PKA/CREB signaling in microglia [PMID:29100790, PMID:40093898]. In the heart, PDE4B blunts beta-adrenergic cAMP/PKA signaling, L-type Ca2+ current, and contraction, and protects against catecholamine- and pressure-overload-induced dysfunction, while also driving neutrophil-endothelial interactions in ischemia-reperfusion injury [PMID:32264695, PMID:35899614]. In B-cell lymphoma, PDE4B inactivates cAMP to abrogate apoptosis through a PKA/EPAC-independent, PI3K/AKT-linked mechanism and participates in a mutually reinforcing feed-forward loop with MYC [PMID:15331441, PMID:31138843].","teleology":[{"year":1997,"claim":"Established that PDE4B is not a single activity but a set of splice variants whose unique N-termini determine where the enzyme localizes and how it behaves enzymatically and pharmacologically.","evidence":"Cloning and expression of HSPDE4B1/2/3 in COS7 cells with fractionation, cAMP hydrolysis, and rolipram inhibition assays","pmids":["9371714"],"confidence":"High","gaps":["Did not resolve isoform-specific signaling partners in vivo","N-terminal targeting determinants not mapped at residue level"]},{"year":2002,"claim":"Answered whether a specific PDE4 isoform controls innate immune cytokine output by showing PDE4B, not PDE4D, is required for LPS-driven TNF-alpha and is itself induced as feedback.","evidence":"PDE4B knockout mice with LPS stimulation, cytokine mRNA/protein, and PDE4 activity assays in macrophages and leukocytes","pmids":["12032334"],"confidence":"High","gaps":["Did not define the transcriptional pathway inducing PDE4B","Compartment of cAMP control not yet identified"]},{"year":2004,"claim":"Showed how PDE4B promotes lymphoma survival by hydrolyzing pro-apoptotic cAMP through a PKA/EPAC-independent, PI3K/AKT-linked route.","evidence":"DLBCL cell lines reconstituted with wild-type/mutant PDE4B, cAMP-induced apoptosis assays, and constitutively active AKT epistasis","pmids":["15331441"],"confidence":"High","gaps":["Mechanistic link between cAMP and AKT not fully defined","Did not address upstream regulation of PDE4B in lymphoma"]},{"year":2005,"claim":"Defined the regulatory logic of PDE4B activation by showing DISC1 sequesters it via UCR2 and releases it upon cAMP elevation, coupling scaffold binding to enzyme activity.","evidence":"Co-immunoprecipitation, UCR2 domain mapping, and cellular cAMP elevation assays","pmids":["16293762"],"confidence":"High","gaps":["Structural basis of UCR2-DISC1 interface not solved","Did not establish physiological cAMP threshold for dissociation"]},{"year":2008,"claim":"Extended the DISC1-PDE4B relationship into a multiprotein scaffold linking local cAMP hydrolysis to PKA phosphorylation of NDE1 at the centrosome and synapses.","evidence":"Co-immunoprecipitation and immunofluorescence in cultured neurons for DISC1/NDE1/NDEL1/LIS1/dynein/PDE4B","pmids":["18983980"],"confidence":"Medium","gaps":["Scaffold stoichiometry inferred, not measured","Direct versus indirect interactions within the complex not resolved"]},{"year":2011,"claim":"Resolved where PDE4B acts by demonstrating it controls cAMP in a near-membrane subdomain that selectively gates TLR signaling without affecting bulk cytosolic cAMP or CREB transcription.","evidence":"PDE4B/PDE4D gene ablation in MEFs with FRET cAMP reporters, phosphoprotein, and transcription reporter assays","pmids":["21288894"],"confidence":"High","gaps":["Molecular anchors tethering PDE4B near the membrane not identified","Did not extend compartment mapping to immune cell types"]},{"year":2011,"claim":"Tied PDE4B function to synaptic plasticity and cognition by showing loss enhances hippocampal LTD and impairs reversal learning.","evidence":"PDE4B knockout mice with hippocampal slice electrophysiology and Morris water maze","pmids":["21458469"],"confidence":"Medium","gaps":["Cell-type and isoform responsible not dissected","cAMP/PKA effectors mediating LTD change not defined"]},{"year":2011,"claim":"Showed DISC1 can co-assemble PDE4B and GSK-3, and that a DISC1 variant reshapes this complex, linking genetic variation to convergent cAMP/GSK-3 signaling.","evidence":"DISC1 Q31L/L100P mutant mice with GSK-3 activity, binding assays, and rolipram/TDZD-8 pharmacological epistasis","pmids":["21376063"],"confidence":"Medium","gaps":["Direct ternary complex not structurally demonstrated","Functional output of converged signaling in vivo incomplete"]},{"year":2009,"claim":"Provided a structural mechanism for inhibition by showing a THBT inhibitor displaces the invariant Gln-443 and shifts helix-15.","evidence":"X-ray co-crystal structure of THBT inhibitor with PDE4B","pmids":["19525117"],"confidence":"High","gaps":["Did not establish isoform selectivity in cells","Conformational dynamics under physiological regulation not addressed"]},{"year":2014,"claim":"Defined a distinct inhibitor mechanism in which triazines engage a C-terminal regulatory helix (CR3) to lock PDE4B in an inactive closed state, enabling subtype-selective design.","evidence":"High-resolution co-crystal structures with SAR analysis","pmids":["24998378"],"confidence":"High","gaps":["Whether CR3 engagement occurs with endogenous regulators unknown","Selectivity over other PDE4 subtypes not validated in vivo"]},{"year":2013,"claim":"Explained an anti-inflammatory mechanism of PDE4B inhibition through JNK2-selective induction of the deubiquitinase CYLD.","evidence":"PDE4 inhibitor treatment, JNK1/JNK2 selective activation, and CYLD-knockout mouse epistasis","pmids":["23575688"],"confidence":"High","gaps":["Connection between cAMP and JNK2 selectivity not detailed","Cell types mediating in vivo effect not fully resolved"]},{"year":2013,"claim":"Identified IL-2/STAT5 as a transcriptional inducer of PDE4B and revealed cell-type-restricted expression in CD8+ T cells with aberrant expression in lymphoid cancers.","evidence":"Microarray, STAT5 ChIP-on-chip, and qRT-PCR in PHA-activated human PBMCs","pmids":["23451206"],"confidence":"Medium","gaps":["Functional consequence of STAT5-driven PDE4B in T cells not tested","Mechanism of aberrant CD4+ cancer expression unknown"]},{"year":2013,"claim":"Established a MYC-PDE4B feed-forward loop sustaining B-lymphoma proliferation and survival, identifying a combinatorial vulnerability.","evidence":"B-lymphoma lines, Emu-myc transgenic mice, co-inhibition, and xenograft experiments","pmids":["31138843"],"confidence":"Medium","gaps":["Direct transcriptional wiring between MYC and PDE4B not mapped","Single-lab in vivo validation"]},{"year":2015,"claim":"Defined a transcriptional induction mechanism for PDE4B2 via PKA-Cbeta phosphorylation of NF-kappaB p65 at Ser276, with both enzymatic and non-enzymatic contributions to chemokine induction.","evidence":"In vitro/in vivo expression, PKA-Cbeta and p65 knockdown/overexpression, Ser276 mutagenesis, and promoter assays","pmids":["25831493"],"confidence":"High","gaps":["Nature of the non-enzymatic chemokine contribution unresolved","Generality across stimuli beyond NTHi/roflumilast not tested"]},{"year":2017,"claim":"Identified Smurf2 as the E3 ligase driving ubiquitin-dependent PDE4B degradation, linking PDE4B turnover to cAMP-PKA-CREB output and downstream anti-fibrotic miR-132/CTGF signaling.","evidence":"Co-IP, transgenic overexpression/knockdown mice, miRNA array, and dual-luciferase assays","pmids":["29100790"],"confidence":"Medium","gaps":["Ubiquitination site on PDE4B not mapped","Reciprocal validation of the Smurf2-PDE4B interaction limited"]},{"year":2025,"claim":"Showed circDlg1 stabilizes PDE4B by forming a ternary complex with Smurf2 through PDE4B's N-terminal targeting domain, sustaining low cAMP and impaired anti-inflammatory PKA/CREB signaling in microglia.","evidence":"RNA pulldown/MS, RIP, Co-IP, domain mapping, and AAV knockdown in APP/PS1 mice with behavior","pmids":["40093898"],"confidence":"Medium","gaps":["Structural basis of the ternary complex not solved","Single-lab in vivo validation"]},{"year":2020,"claim":"Demonstrated PDE4B restrains cardiac beta-adrenergic cAMP/PKA signaling and Ca2+ handling, with moderate overexpression protecting against heart failure phenotypes.","evidence":"Cardiomyocyte-specific transgenic and AAV9 PDE4B mice with FRET imaging, patch-clamp, and isoproterenol/TAC disease models","pmids":["32264695"],"confidence":"High","gaps":["Endogenous PDE4B compartmentation in cardiomyocytes not fully defined","Therapeutic window of overexpression not established"]},{"year":2020,"claim":"Showed PDE4B drives neutrophil-endothelial interactions and microvascular dysfunction in myocardial ischemia-reperfusion via PKA-dependent adhesion molecule expression, with NO-dependent vasodilatory effects upon blockade.","evidence":"PDE4B knockout mice with bone marrow chimeras, reperfusion model, and human coronary vasomotor assays","pmids":["35899614"],"confidence":"High","gaps":["Cell-intrinsic versus endothelial contributions only partly separated","Adhesion molecule targets not exhaustively mapped"]},{"year":2016,"claim":"Linked PDE4B to neuroinflammation and gut-CNS crosstalk after spinal cord injury, with deletion reducing ER stress, inflammation, dysbiosis, and improving white matter sparing.","evidence":"Pde4b knockout mice with thoracic contusion SCI, molecular markers, microbiome sequencing, and locomotor recovery","pmids":["30557659"],"confidence":"Medium","gaps":["Cellular source of pathogenic PDE4B in cord not defined","Causal direction of gut-CNS axis not fully established"]},{"year":2016,"claim":"Established a metabolic role for PDE4B in alcohol-induced hepatic steatosis through cAMP suppression of fatty-acid oxidation via the Pparalpha/Sirt1/Pgc1alpha axis.","evidence":"Pde4b knockout mice with alcohol feeding, hepatic cAMP and gene expression analysis, and rolipram treatment","pmids":["27287961"],"confidence":"Medium","gaps":["Direct PDE4B target compartment in hepatocytes not defined","Isoform responsible not identified"]},{"year":2022,"claim":"Showed PDE4B is the dominant dendritic-cell phosphodiesterase acting as a PKA-dependent homeostatic cAMP buffer.","evidence":"Gas-depleted DC mouse model, PKA inhibitor experiments, and PDE4B inhibitor with T cell readouts","pmids":["35387344"],"confidence":"Medium","gaps":["Transcriptional mechanism of homeostatic feedback not defined","Impact on antigen-specific responses limited"]},{"year":2021,"claim":"Identified NFATc2 as a required transcription factor for LPS-induced PDE4B in macrophages and tied its temporal dynamics to lung injury and reparative reprogramming.","evidence":"RNA-seq of sorted macrophages, NFATc2 inhibition, intratracheal rolipram, monocyte depletion, and adoptive transfer","pmids":["34318714"],"confidence":"Medium","gaps":["Direct NFATc2 binding to the PDE4B locus not shown","Isoform induced not specified"]},{"year":2025,"claim":"Mapped a circuit-level role for Pde4b in stress-induced anxiety through cAMP signaling in an auditory-to-somatosensory GABAergic projection.","evidence":"Single-cell and spatial transcriptomics, targeted Pde4b knockdown, optogenetics/chemogenetics, and behavior","pmids":["39891910"],"confidence":"Medium","gaps":["Downstream cAMP effectors in the circuit not defined","Isoform specificity not resolved"]},{"year":2024,"claim":"Provided genetic evidence that reduced PDE4B activity is protective in Alzheimer's models, with a hypomorphic Y358C allele preventing memory and metabolic deficits independent of amyloid.","evidence":"AppNL-G-F mice crossed with Pde4bY358C hypomorphs, Barnes maze, deoxyglucose autoradiography, and RNA-seq","pmids":["38521860"],"confidence":"Medium","gaps":["Mechanism linking cAMP to the protective transcriptomic signature unclear","Relevance of identified DEGs not functionally tested"]},{"year":2024,"claim":"Connected a hypofunctional PDE4B missense variant (M220T) to PTSD-relevant behavior, linking attenuated cAMP hydrolysis to altered fear and sensorimotor gating.","evidence":"HEK-293 cAMP assays of PDE4B1-M220T and homozygous knock-in mice with behavioral battery","pmids":["39256048"],"confidence":"Medium","gaps":["Circuit basis of the behavioral phenotype not localized","Human genetic association not established within this study"]},{"year":null,"claim":"How distinct PDE4B isoforms and their N-terminal targeting determinants are matched to specific cAMP microdomains, scaffolds, and effector outputs across tissues remains incompletely defined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified map of isoform-specific anchoring partners across cell types","Endogenous structural state coupling regulation and catalysis not resolved","Whether selective inhibitor conformations recapitulate physiological regulation is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[2,5,28]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[2,5]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,8,9]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[10,11]}],"complexes":["DISC1-PDE4B-NDE1-NDEL1-LIS1-dynein scaffold complex"],"partners":["DISC1","SMURF2","NDE1","NDEL1","LIS1","GSK3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q07343","full_name":"3',5'-cyclic-AMP phosphodiesterase 4B","aliases":["DPDE4","PDE32","cAMP-specific phosphodiesterase 4B"],"length_aa":736,"mass_kda":83.3,"function":"Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes (PubMed:15260978). May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents","subcellular_location":"Cytoplasm; Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q07343/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PDE4B","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PDE4B","total_profiled":1310},"omim":[{"mim_id":"613735","title":"BRAIN MALFORMATIONS WITH OR WITHOUT URINARY TRACT DEFECTS; BRMUTD","url":"https://www.omim.org/entry/613735"},{"mim_id":"605210","title":"DISC1 SCAFFOLD PROTEIN; DISC1","url":"https://www.omim.org/entry/605210"},{"mim_id":"602973","title":"PHOSPHODIESTERASE 9A; PDE9A","url":"https://www.omim.org/entry/602973"},{"mim_id":"602972","title":"PHOSPHODIESTERASE 8A; PDE8A","url":"https://www.omim.org/entry/602972"},{"mim_id":"600129","title":"PHOSPHODIESTERASE 4D; PDE4D","url":"https://www.omim.org/entry/600129"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":71.3}],"url":"https://www.proteinatlas.org/search/PDE4B"},"hgnc":{"alias_symbol":[],"prev_symbol":["DPDE4"]},"alphafold":{"accession":"Q07343","domains":[{"cath_id":"1.10.1300.10","chopping":"334-654","consensus_level":"medium","plddt":96.6361,"start":334,"end":654}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07343","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07343-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07343-F1-predicted_aligned_error_v6.png","plddt_mean":70.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PDE4B","jax_strain_url":"https://www.jax.org/strain/search?query=PDE4B"},"sequence":{"accession":"Q07343","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07343.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07343/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07343"}},"corpus_meta":[{"pmid":"16293762","id":"PMC_16293762","title":"DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16293762","citation_count":523,"is_preprint":false},{"pmid":"12032334","id":"PMC_12032334","title":"Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12032334","citation_count":285,"is_preprint":false},{"pmid":"17700644","id":"PMC_17700644","title":"Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B).","date":"2007","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17700644","citation_count":150,"is_preprint":false},{"pmid":"15331441","id":"PMC_15331441","title":"The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15331441","citation_count":133,"is_preprint":false},{"pmid":"10602317","id":"PMC_10602317","title":"Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.","date":"1999","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10602317","citation_count":117,"is_preprint":false},{"pmid":"35517783","id":"PMC_35517783","title":"BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35517783","citation_count":109,"is_preprint":false},{"pmid":"18394866","id":"PMC_18394866","title":"PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia.","date":"2008","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/18394866","citation_count":100,"is_preprint":false},{"pmid":"18060387","id":"PMC_18060387","title":"Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.","date":"2007","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18060387","citation_count":91,"is_preprint":false},{"pmid":"22384243","id":"PMC_22384243","title":"ZNF804a regulates expression of the schizophrenia-associated genes PRSS16, COMT, PDE4B, and DRD2.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22384243","citation_count":85,"is_preprint":false},{"pmid":"9371714","id":"PMC_9371714","title":"Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.","date":"1997","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9371714","citation_count":82,"is_preprint":false},{"pmid":"27038323","id":"PMC_27038323","title":"PDE4B as a microglia target to reduce neuroinflammation.","date":"2016","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/27038323","citation_count":82,"is_preprint":false},{"pmid":"32264695","id":"PMC_32264695","title":"Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure.","date":"2020","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/32264695","citation_count":75,"is_preprint":false},{"pmid":"18983980","id":"PMC_18983980","title":"DISC1, PDE4B, and NDE1 at the centrosome and synapse.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18983980","citation_count":74,"is_preprint":false},{"pmid":"17333137","id":"PMC_17333137","title":"Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.","date":"2007","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17333137","citation_count":73,"is_preprint":false},{"pmid":"17417055","id":"PMC_17417055","title":"The PDE4B gene confers sex-specific protection against schizophrenia.","date":"2007","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17417055","citation_count":72,"is_preprint":false},{"pmid":"30557659","id":"PMC_30557659","title":"Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia.","date":"2018","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30557659","citation_count":67,"is_preprint":false},{"pmid":"18687753","id":"PMC_18687753","title":"Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease.","date":"2008","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18687753","citation_count":65,"is_preprint":false},{"pmid":"22160351","id":"PMC_22160351","title":"Association of PDE4B polymorphisms and schizophrenia in Northwestern Han Chinese.","date":"2011","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22160351","citation_count":65,"is_preprint":false},{"pmid":"21376063","id":"PMC_21376063","title":"Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice.","date":"2011","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21376063","citation_count":63,"is_preprint":false},{"pmid":"28054669","id":"PMC_28054669","title":"Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28054669","citation_count":63,"is_preprint":false},{"pmid":"35899614","id":"PMC_35899614","title":"Targeting PDE4B (Phosphodiesterase-4 Subtype B) for Cardioprotection in Acute Myocardial Infarction via Neutrophils and Microcirculation.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/35899614","citation_count":52,"is_preprint":false},{"pmid":"23575688","id":"PMC_23575688","title":"Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/23575688","citation_count":52,"is_preprint":false},{"pmid":"21288894","id":"PMC_21288894","title":"PDE4D and PDE4B function in distinct subcellular compartments in mouse embryonic fibroblasts.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21288894","citation_count":51,"is_preprint":false},{"pmid":"21458469","id":"PMC_21458469","title":"Enhanced long-term depression and impaired reversal learning in phosphodiesterase 4B-knockout (PDE4B-/-) mice.","date":"2011","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21458469","citation_count":47,"is_preprint":false},{"pmid":"27287961","id":"PMC_27287961","title":"Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis.","date":"2016","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27287961","citation_count":45,"is_preprint":false},{"pmid":"19525117","id":"PMC_19525117","title":"Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode.","date":"2009","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19525117","citation_count":45,"is_preprint":false},{"pmid":"29100790","id":"PMC_29100790","title":"Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and attenuates liver fibrosis through miR-132 mediated CTGF inhibition.","date":"2017","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29100790","citation_count":43,"is_preprint":false},{"pmid":"36278172","id":"PMC_36278172","title":"The regulatory role of PDE4B in the progression of inflammatory function study.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36278172","citation_count":42,"is_preprint":false},{"pmid":"18329668","id":"PMC_18329668","title":"Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the Japanese population.","date":"2008","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/18329668","citation_count":40,"is_preprint":false},{"pmid":"24998378","id":"PMC_24998378","title":"Discovery of triazines as selective PDE4B versus PDE4D inhibitors.","date":"2014","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24998378","citation_count":40,"is_preprint":false},{"pmid":"33522352","id":"PMC_33522352","title":"Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of Parkinson's disease.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/33522352","citation_count":39,"is_preprint":false},{"pmid":"25831493","id":"PMC_25831493","title":"Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25831493","citation_count":38,"is_preprint":false},{"pmid":"35957809","id":"PMC_35957809","title":"LncRNA GAS5 Knockdown Mitigates Hepatic Lipid Accumulation via Regulating MiR-26a-5p/PDE4B to Activate cAMP/CREB Pathway.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35957809","citation_count":33,"is_preprint":false},{"pmid":"27665850","id":"PMC_27665850","title":"Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP/CREB signaling pathway in PC12 cells.","date":"2016","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/27665850","citation_count":33,"is_preprint":false},{"pmid":"31961716","id":"PMC_31961716","title":"Inhibition of PDE4/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury.","date":"2020","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31961716","citation_count":32,"is_preprint":false},{"pmid":"7835077","id":"PMC_7835077","title":"Chromosomal localization of the human and rat genes (PDE4D and PDE4B) encoding the cAMP-specific phosphodiesterases 3 and 4.","date":"1995","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7835077","citation_count":31,"is_preprint":false},{"pmid":"12469939","id":"PMC_12469939","title":"DMSO-treated HL60 cells: a model of neutrophil-like cells mainly expressing PDE4B subtype.","date":"2002","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12469939","citation_count":31,"is_preprint":false},{"pmid":"19350560","id":"PMC_19350560","title":"Association study of PDE4B gene variants in Scandinavian schizophrenia and bipolar disorder multicenter case-control samples.","date":"2010","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19350560","citation_count":29,"is_preprint":false},{"pmid":"29197324","id":"PMC_29197324","title":"Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus.","date":"2017","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29197324","citation_count":29,"is_preprint":false},{"pmid":"39183442","id":"PMC_39183442","title":"PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells.","date":"2024","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39183442","citation_count":28,"is_preprint":false},{"pmid":"17960764","id":"PMC_17960764","title":"Differential distribution of PDE4B splice variant mRNAs in rat brain and the effects of systemic administration of LPS in their expression.","date":"2008","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17960764","citation_count":28,"is_preprint":false},{"pmid":"22529021","id":"PMC_22529021","title":"Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer.","date":"2011","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/22529021","citation_count":27,"is_preprint":false},{"pmid":"31035240","id":"PMC_31035240","title":"InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.","date":"2019","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31035240","citation_count":27,"is_preprint":false},{"pmid":"32622666","id":"PMC_32622666","title":"Rutaecarpine derivative Cpd-6c alleviates acute kidney injury by targeting PDE4B, a key enzyme mediating inflammation in cisplatin nephropathy.","date":"2020","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32622666","citation_count":27,"is_preprint":false},{"pmid":"34506801","id":"PMC_34506801","title":"Declines in PDE4B activity promote myopia progression through downregulation of scleral collagen expression.","date":"2021","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/34506801","citation_count":23,"is_preprint":false},{"pmid":"24215890","id":"PMC_24215890","title":"Synthesis and biological evaluation of nimesulide based new class of triazole derivatives as potential PDE4B inhibitors against cancer cells.","date":"2013","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24215890","citation_count":23,"is_preprint":false},{"pmid":"36737782","id":"PMC_36737782","title":"Loss of miR-26b-5p promotes gastric cancer progression via miR-26b-5p-PDE4B/CDK8-STAT3 feedback loop.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36737782","citation_count":22,"is_preprint":false},{"pmid":"25019986","id":"PMC_25019986","title":"Blockade of PDE4B limits lung vascular permeability and lung inflammation in LPS-induced acute lung injury.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25019986","citation_count":21,"is_preprint":false},{"pmid":"34064099","id":"PMC_34064099","title":"Selective Inhibition of PDE4B Reduces Binge Drinking in Two C57BL/6 Substrains.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34064099","citation_count":20,"is_preprint":false},{"pmid":"23436140","id":"PMC_23436140","title":"Novel N-indolylmethyl substituted olanzapine derivatives: their design, synthesis and evaluation as PDE4B inhibitors.","date":"2013","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23436140","citation_count":20,"is_preprint":false},{"pmid":"34977026","id":"PMC_34977026","title":"PDE4B Induces Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Is Transcriptionally Suppressed by CBX7.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34977026","citation_count":19,"is_preprint":false},{"pmid":"15829230","id":"PMC_15829230","title":"Phosphodiesterase 4B (PDE4B) and cAMP-level regulation within different tissue fractions of rat hippocampal slices during long-term potentiation in vitro.","date":"2005","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15829230","citation_count":19,"is_preprint":false},{"pmid":"38521860","id":"PMC_38521860","title":"Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer's disease.","date":"2024","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38521860","citation_count":18,"is_preprint":false},{"pmid":"35063752","id":"PMC_35063752","title":"MiR-124-3p targeting PDE4B attenuates LPS-induced ALI through the TLR4/NF-κB signaling pathway.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35063752","citation_count":18,"is_preprint":false},{"pmid":"30628641","id":"PMC_30628641","title":"Anti‑inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30628641","citation_count":18,"is_preprint":false},{"pmid":"25769842","id":"PMC_25769842","title":"Venlafaxine increases cell proliferation and regulates DISC1, PDE4B and NMDA receptor 2B expression in the hippocampus in chronic mild stress mice.","date":"2015","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25769842","citation_count":18,"is_preprint":false},{"pmid":"29867490","id":"PMC_29867490","title":"A Novel Catecholopyrimidine Based Small Molecule PDE4B Inhibitor Suppresses Inflammatory Cytokines in Atopic Mice.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29867490","citation_count":18,"is_preprint":false},{"pmid":"33144067","id":"PMC_33144067","title":"Low concentration of Bupivacaine ameliorates painful diabetic neuropathy by mediating miR-23a/PDE4B axis in microglia.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33144067","citation_count":17,"is_preprint":false},{"pmid":"29477888","id":"PMC_29477888","title":"Synthesis and molecular docking of new roflumilast analogues as preferential-selective potent PDE-4B inhibitors with improved pharmacokinetic profile.","date":"2018","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29477888","citation_count":17,"is_preprint":false},{"pmid":"31138843","id":"PMC_31138843","title":"Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/31138843","citation_count":16,"is_preprint":false},{"pmid":"35046895","id":"PMC_35046895","title":"qPCR Analysis Reveals Association of Differential Expression of SRR, NFKB1, and PDE4B Genes With Type 2 Diabetes Mellitus.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35046895","citation_count":16,"is_preprint":false},{"pmid":"34271099","id":"PMC_34271099","title":"Gut probiotic Lactobacillus rhamnosus attenuates PDE4B-mediated interleukin-6 induced by SARS-CoV-2 membrane glycoprotein.","date":"2021","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34271099","citation_count":16,"is_preprint":false},{"pmid":"33809405","id":"PMC_33809405","title":"Rolipram Prevents the Formation of Abdominal Aortic Aneurysm (AAA) in Mice: PDE4B as a Target in AAA.","date":"2021","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33809405","citation_count":16,"is_preprint":false},{"pmid":"23451206","id":"PMC_23451206","title":"Genome wide mapping reveals PDE4B as an IL-2 induced STAT5 target gene in activated human PBMCs and lymphoid cancer cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23451206","citation_count":15,"is_preprint":false},{"pmid":"36145643","id":"PMC_36145643","title":"Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease.","date":"2022","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/36145643","citation_count":14,"is_preprint":false},{"pmid":"34318714","id":"PMC_34318714","title":"Evidence for reprogramming of monocytes into reparative alveolar macrophages in vivo by targeting PDE4b.","date":"2021","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34318714","citation_count":14,"is_preprint":false},{"pmid":"32038254","id":"PMC_32038254","title":"Identification of a Selective PDE4B Inhibitor From Bryophyllum pinnatum by Target Fishing Study and In Vitro Evaluation of Quercetin 3-O-α-L-Arabinopyranosyl-(1→2)-O-α-L-Rhamnopyranoside.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32038254","citation_count":14,"is_preprint":false},{"pmid":"10837797","id":"PMC_10837797","title":"Noradrenergic lesions differentially alter the expression of two subtypes of low Km cAMP-sensitive phosphodiesterase type 4 (PDE4A and PDE4B) in rat brain.","date":"2000","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10837797","citation_count":12,"is_preprint":false},{"pmid":"34323638","id":"PMC_34323638","title":"Discovery of polymethoxyflavones as potential cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX) and phosphodiesterase 4B (PDE4B) inhibitors.","date":"2021","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/34323638","citation_count":11,"is_preprint":false},{"pmid":"35660249","id":"PMC_35660249","title":"Novel quinoline-based derivatives: A new class of PDE4B inhibitors for adjuvant-induced arthritis.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35660249","citation_count":11,"is_preprint":false},{"pmid":"30131242","id":"PMC_30131242","title":"Tetrahydroquinoline and tetrahydroisoquinoline derivatives as potential selective PDE4B inhibitors.","date":"2018","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/30131242","citation_count":10,"is_preprint":false},{"pmid":"39126032","id":"PMC_39126032","title":"Anti-Inflammatory Effects of miR-369-3p via PDE4B in Intestinal Inflammatory Response.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39126032","citation_count":10,"is_preprint":false},{"pmid":"18593531","id":"PMC_18593531","title":"Minimizing a QTL region for intramuscular fat content by characterizing the porcine Phosphodiesterase 4B (PDE4B) gene.","date":"2008","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/18593531","citation_count":10,"is_preprint":false},{"pmid":"24440301","id":"PMC_24440301","title":"Synthesis of 2H-1,3-benzoxazin-4(3H)-one derivatives containing indole moiety: their in vitro evaluation against PDE4B.","date":"2014","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24440301","citation_count":10,"is_preprint":false},{"pmid":"39408735","id":"PMC_39408735","title":"Nobiletin, as a Novel PDE4B Inhibitor, Alleviates Asthma Symptoms by Activating the cAMP-PKA-CREB Signaling Pathway.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39408735","citation_count":9,"is_preprint":false},{"pmid":"36935006","id":"PMC_36935006","title":"Selective PDE4B and PDE4D inhibitors produce distinct behavioral responses to ethanol and GABAergic drugs in mice.","date":"2023","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36935006","citation_count":9,"is_preprint":false},{"pmid":"35116054","id":"PMC_35116054","title":"PDE4B Proposed as a High Myopia Susceptibility Gene in Chinese Population.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35116054","citation_count":9,"is_preprint":false},{"pmid":"35387344","id":"PMC_35387344","title":"PDE4B Is a Homeostatic Regulator of Cyclic AMP in Dendritic Cells.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35387344","citation_count":9,"is_preprint":false},{"pmid":"40093898","id":"PMC_40093898","title":"Microglial circDlg1 modulates neuroinflammation by blocking PDE4B ubiquitination-dependent degradation associated with Alzheimer's disease.","date":"2025","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/40093898","citation_count":8,"is_preprint":false},{"pmid":"21184794","id":"PMC_21184794","title":"Association study of PDE4B with panic disorder in the Japanese population.","date":"2010","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21184794","citation_count":8,"is_preprint":false},{"pmid":"35266293","id":"PMC_35266293","title":"Population genetics of PDE4B (phosphodiesterase-4B) in neglected Native Americans: Implications for cancer pharmacogenetics.","date":"2022","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/35266293","citation_count":7,"is_preprint":false},{"pmid":"29175029","id":"PMC_29175029","title":"Depletion of D3 dopamine receptor affects methamphetamine-induced expression patterns of Pde4b and Atf3.","date":"2017","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/29175029","citation_count":6,"is_preprint":false},{"pmid":"39893206","id":"PMC_39893206","title":"PDE4B promotes ferroptosis in nucleus pulposus cells and is involved in intervertebral disc degeneration.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39893206","citation_count":6,"is_preprint":false},{"pmid":"39467506","id":"PMC_39467506","title":"Rationale design and synthesis of new roflumilast analogues as preferential selective and potent PDE-4B inhibitors.","date":"2024","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39467506","citation_count":6,"is_preprint":false},{"pmid":"25748781","id":"PMC_25748781","title":"Design, synthesis and biological evaluation of novel quinazoline-based anti-inflammatory agents acting as PDE4B inhibitors.","date":"2015","source":"Chemical & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/25748781","citation_count":6,"is_preprint":false},{"pmid":"39787692","id":"PMC_39787692","title":"Shenghui decoction inhibits neuronal cell apoptosis to improve Alzheimer's disease through the PDE4B/cAMP/CREB signaling pathway.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39787692","citation_count":5,"is_preprint":false},{"pmid":"38920631","id":"PMC_38920631","title":"Early Inhibition of Phosphodiesterase 4B (PDE4B) Instills Cognitive Resilience in APPswe/PS1dE9 Mice.","date":"2024","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38920631","citation_count":5,"is_preprint":false},{"pmid":"41255094","id":"PMC_41255094","title":"Nerandomilast, a PDE4B inhibitor, alleviates silica-induced lung inflammation and fibrosis by inhibition of NLRP3 inflammasome and TGF-β/Smad signalling.","date":"2025","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41255094","citation_count":4,"is_preprint":false},{"pmid":"30413022","id":"PMC_30413022","title":"Dexamethasone Inhibits Synergistic Induction of PDE4B Expression by Roflumilast and Bacterium NTHi.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30413022","citation_count":4,"is_preprint":false},{"pmid":"39256048","id":"PMC_39256048","title":"PDE4B Missense Variant Increases Susceptibility to Post-traumatic Stress Disorder-Relevant Phenotypes in Mice.","date":"2024","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/39256048","citation_count":4,"is_preprint":false},{"pmid":"25926551","id":"PMC_25926551","title":"Association analysis of PDE4B polymorphisms with schizophrenia and smooth pursuit eye movement abnormality in a Korean population.","date":"2015","source":"General physiology and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/25926551","citation_count":4,"is_preprint":false},{"pmid":"31663033","id":"PMC_31663033","title":"PDE4B gene polymorphism in Russian patients with panic disorder.","date":"2019","source":"AIMS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31663033","citation_count":4,"is_preprint":false},{"pmid":"38523176","id":"PMC_38523176","title":"Zoledronic Acid Accelerates ER Stress-Mediated Inflammation by Increasing PDE4B Expression in Bisphosphonate-Related Osteonecrosis of the Jaw.","date":"2024","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38523176","citation_count":4,"is_preprint":false},{"pmid":"30394213","id":"PMC_30394213","title":"Exploring the Role of Water Molecules in the Ligand Binding Domain of PDE4B and PDE4D: Virtual Screening Based Molecular Docking of Some Active Scaffolds.","date":"2019","source":"Current computer-aided drug design","url":"https://pubmed.ncbi.nlm.nih.gov/30394213","citation_count":4,"is_preprint":false},{"pmid":"39523465","id":"PMC_39523465","title":"COF-SO3H-Catalyzed Synthesis of Pyrazoline-Pyridine Hybrids with Dual Antioxidant and Anti-Inflammatory Activity Targeting PDE4B.","date":"2024","source":"Chemistry & biodiversity","url":"https://pubmed.ncbi.nlm.nih.gov/39523465","citation_count":4,"is_preprint":false},{"pmid":"26613238","id":"PMC_26613238","title":"Synthesis of New Congeners of 1-methyl-3-aminoisoquinolines, Evaluation of Their Cytotoxic Activity, In Silico and In Vitro Study of Their Molecular Targets as PDE4B.","date":"2015","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/26613238","citation_count":4,"is_preprint":false},{"pmid":"40654275","id":"PMC_40654275","title":"PDE4B Inhibition: Exploring the Landscape of Chemistry Behind Specific PDE4B Inhibitors, Drug Design, and Discovery.","date":"2025","source":"Archiv der Pharmazie","url":"https://pubmed.ncbi.nlm.nih.gov/40654275","citation_count":3,"is_preprint":false},{"pmid":"41497055","id":"PMC_41497055","title":"Jascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis.","date":"2025","source":"Annals of medicine and surgery (2012)","url":"https://pubmed.ncbi.nlm.nih.gov/41497055","citation_count":3,"is_preprint":false},{"pmid":"39891910","id":"PMC_39891910","title":"Pde4b-regulated cAMP signaling pathway in the AUDGABA-S1TrSst circuit underlies acute-stress-induced anxiety-like behavior.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39891910","citation_count":3,"is_preprint":false},{"pmid":"35401806","id":"PMC_35401806","title":"Transcription factor JDP2 activates PDE4B to participate in hypoxia/reoxygenation-induced H9c2 cell injury.","date":"2022","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35401806","citation_count":3,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53800,"output_tokens":8033,"usd":0.140948,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17777,"output_tokens":7166,"usd":0.134018,"stage2_stop_reason":"end_turn"},"total_usd":0.274966,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"DISC1 physically interacts with the UCR2 domain of PDE4B, sequestering it in resting cells; elevation of cellular cAMP causes dissociation of PDE4B from DISC1 and an increase in PDE4B enzymatic activity.\",\n      \"method\": \"Co-immunoprecipitation, domain-mapping, cellular cAMP elevation assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal interaction mapped to UCR2 domain, functional consequence (activity change) demonstrated, widely replicated by subsequent studies\",\n      \"pmids\": [\"16293762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PDE4B (but not PDE4D) is required for LPS-induced TNF-alpha production in peripheral leukocytes and macrophages; LPS stimulation induces PDE4B mRNA accumulation and increases PDE4 enzymatic activity, constituting a feedback regulation essential for the innate immune response.\",\n      \"method\": \"PDE4B knockout mice, LPS stimulation, cytokine measurement (TNF-alpha mRNA and protein), PDE4 activity assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with specific phenotypic readout, multiple cell types tested, multiple orthogonal methods (mRNA, protein, enzyme activity)\",\n      \"pmids\": [\"12032334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Three human PDE4B splice variants (HSPDE4B1, HSPDE4B2, HSPDE4B3) differ in their unique N-terminal regions, subcellular distribution (cytosol vs. particulate fractions), maximal cAMP hydrolytic activity, and sensitivity to rolipram inhibition; the N-terminal splice region determines these isoform-specific properties.\",\n      \"method\": \"Molecular cloning, transient expression in COS7 cells, subcellular fractionation, cAMP hydrolysis assay, rolipram inhibition assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic reconstitution with isoform comparisons, fractionation, and inhibitor assays in a single rigorous study\",\n      \"pmids\": [\"9371714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PDE4B inactivates cAMP to abrogate cAMP-induced apoptosis in diffuse large B-cell lymphoma (DLBCL); this cAMP-mediated apoptosis is largely independent of PKA and EPAC but associated with inhibition of the PI3K/AKT pathway, with AKT centrally required as confirmed by constitutively active AKT mutants.\",\n      \"method\": \"DLBCL cell lines reconstituted with wild-type or mutant PDE4B, cAMP-induced apoptosis assay, PI3K/AKT pathway analysis, constitutively active AKT mutant expression\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution with wild-type and mutant PDE4B, epistasis via constitutively active AKT, multiple orthogonal methods in one study\",\n      \"pmids\": [\"15331441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"DISC1, NDE1, NDEL1, LIS1, and dynein associate with PDE4B and PDE4D within cells; this complex localizes to the centrosome and to synapses in cultured neurons. NDE1 is phosphorylated by PKA whose activity is regulated by PDE4-mediated cAMP hydrolysis, suggesting DISC1 acts as a scaffold assembling these proteins.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence localization in cultured neurons\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and direct localization, single lab, mechanistic interpretation partially inferred\",\n      \"pmids\": [\"18983980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PDE4B controls cAMP specifically in a near-membrane subdomain in mouse embryonic fibroblasts; PDE4B ablation increases basal and hormone-dependent cAMP near the plasma membrane but not in bulk cytosol, and selectively affects Toll-like receptor signaling but not CREB-mediated transcription.\",\n      \"method\": \"PDE4B/PDE4D gene ablation in mouse embryonic fibroblasts, subcellular cAMP reporter assays (FRET-based), phosphoprotein analysis, transcription reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic ablation with subcellular FRET-based cAMP measurement, multiple orthogonal readouts showing compartment-specific function\",\n      \"pmids\": [\"21288894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Co-crystal structure of a tetrahydrobenzothiophene (THBT) inhibitor with PDE4B revealed an unprecedented binding mode in which the ligand displaces the invariant Gln-443 residue and shifts helix-15 by 1-2 Å; C-terminal residues previously proposed to confer subtype selectivity are resolved and extend into the ligand binding site.\",\n      \"method\": \"X-ray co-crystal structure determination\",\n      \"journal\": \"Bioorganic & medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional binding mode, novel structural finding, single study\",\n      \"pmids\": [\"19525117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"High-resolution co-crystal structure of triazine PDE4B inhibitors shows that they interact with both the catalytic domain and a C-terminal regulatory helix (CR3), locking the enzyme in an inactive 'closed' conformation; this provides a structural basis for PDE4B-selective inhibitor design.\",\n      \"method\": \"X-ray co-crystal structure determination, structure-activity relationship analysis\",\n      \"journal\": \"Bioorganic & medicinal chemistry letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with defined inactive conformation mechanism, single study with SAR support\",\n      \"pmids\": [\"24998378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD; PDE4B negatively regulates CYLD via specific activation of JNK2 (but not JNK1); in CYLD-deficient mice, PDE4B inhibition no longer suppresses inflammation.\",\n      \"method\": \"PDE4 inhibitor treatment, CYLD expression assay, JNK1/JNK2 selective activation, CYLD-knockout mice\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (CYLD KO), pathway dissection (JNK1 vs JNK2), multiple orthogonal methods including in vivo validation\",\n      \"pmids\": [\"23575688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Roflumilast synergizes with NTHi to up-regulate PDE4B2 expression via a PKA catalytic subunit β (PKA-Cβ) / NF-κB p65 cross-talk; PKA-Cβ phosphorylates p65 in a cAMP-dependent manner at Ser276, which is critical for synergistic PDE4B2 induction; up-regulated PDE4B2 contributes to chemokine induction in both enzymatic activity-dependent and -independent manners.\",\n      \"method\": \"In vitro and in vivo gene expression studies, PKA-Cβ and p65 knockdown/overexpression, site-directed mutagenesis (Ser276), promoter assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis, pathway epistasis (PKA-Cβ knockdown), in vitro and in vivo confirmation, single lab with multiple methods\",\n      \"pmids\": [\"25831493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Smurf2 (E3 ubiquitin ligase) interacts with PDE4B and facilitates its ubiquitination-dependent degradation, thereby activating the cAMP-PKA-CREB pathway; elevated cAMP increases miR-132 expression, which targets CTGF to suppress liver fibrosis.\",\n      \"method\": \"Co-immunoprecipitation, overexpression/knockdown in transgenic mice, miRNA array, dual-luciferase assay, western blot\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP interaction, in vivo transgenic model, miRNA target validation; single lab\",\n      \"pmids\": [\"29100790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CircDlg1 (a circular RNA) forms a ternary complex with PDE4B and Smurf2, blocking Smurf2-mediated ubiquitination and degradation of PDE4B via PDE4B's unique N-terminal targeting domain; elevated PDE4B reduces cAMP and suppresses PKA/CREB anti-inflammatory signaling in microglia.\",\n      \"method\": \"RNA pulldown, mass spectrometry, RNA immunoprecipitation, co-immunoprecipitation, AAV-mediated knockdown in APP/PS1 mice, behavioral testing\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, pulldown, domain mapping, in vivo validation; single lab\",\n      \"pmids\": [\"40093898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PDE4B mediates neutrophil-endothelial cell interaction in myocardial ischemia-reperfusion (MI/R) injury via PKA-dependent expression of cell adhesion molecules, promotes neutrophil cardiac infiltration, and promotes coronary microcirculatory obstruction and vascular permeability; PDE4B blockade increases flow-mediated vasodilatation in a PKA- and nitric oxide-dependent manner.\",\n      \"method\": \"PDE4B knockout mice, bone marrow transplant (cell-specific rescue), coronary artery ligation/reperfusion model, laser Doppler flow, patch-clamp, vasomotor reactivity assays in mouse and human coronary arteries\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with bone marrow chimera for cell-type dissection, human tissue validation, multiple orthogonal functional readouts\",\n      \"pmids\": [\"35899614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cardiac overexpression of PDE4B blunts beta-adrenergic receptor stimulation of cAMP, PKA activity, L-type Ca2+ current, Ca2+ transients, and cell contraction; moderate PDE4B overexpression protects against isoproterenol- and pressure overload-induced systolic dysfunction, hypertrophy, fibrosis, and apoptosis.\",\n      \"method\": \"Transgenic mouse lines with cardiomyocyte-specific PDE4B overexpression, AAV9-PDE4B gene delivery, echocardiography, FRET-based cAMP and PKA imaging, whole-cell patch-clamp, isoproterenol infusion and transverse aortic constriction models\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple transgenic lines, AAV gene therapy model, FRET cAMP imaging, patch-clamp, multiple disease models, multiple orthogonal methods\",\n      \"pmids\": [\"32264695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PDE4B and GSK-3 both bind the N-terminal region of DISC1 and can converge signals via DISC1 simultaneously; DISC1 Q31L mutation reduces PDE4B binding and increases GSK-3 enzymatic activity, demonstrating that DISC1 genetic variation influences the biochemical complex with PDE4B and GSK-3.\",\n      \"method\": \"Double-mutant DISC1 mouse models (Q31L and L100P), biochemical analysis of GSK-3 activity and DISC1 binding, pharmacological epistasis (rolipram + TDZD-8)\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with DISC1 mutant mice, biochemical interaction analysis, pharmacological synergy; single lab\",\n      \"pmids\": [\"21376063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PDE4B knockout mice display enhanced long-term depression (LTD) and increased basal postsynaptic responses in hippocampal slices, but no change in LTP; behaviorally, PDE4B-/- mice show impaired reversal learning in the Morris water maze but normal spatial memory acquisition.\",\n      \"method\": \"PDE4B knockout mice, hippocampal slice electrophysiology (LTP/LTD protocols), Morris water maze\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with electrophysiology and behavioral readouts, single lab\",\n      \"pmids\": [\"21458469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PDE4B knockout mice show decreased striatal dopamine and serotonin levels, decreased prepulse inhibition (PPI), decreased baseline locomotor activity, and an exaggerated locomotor response to high-dose amphetamine; PDE4B is required for normal PDE4 catalytic activity in multiple brain regions.\",\n      \"method\": \"PDE4B knockout mice, monoamine measurement, PPI assay, locomotor activity, amphetamine challenge\",\n      \"journal\": \"Psychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with neurochemical and behavioral phenotyping, single lab, multiple readouts\",\n      \"pmids\": [\"18060387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PDE4B mediates at least part of the antipsychotic-like effects of rolipram: rolipram suppresses conditioned avoidance responding (CAR) in wild-type mice but with a 3-fold shift in ED50 in PDE4B knockout mice, demonstrating PDE4B involvement in rolipram's mechanism of action.\",\n      \"method\": \"PDE4B knockout mice, conditioned avoidance responding assay, rolipram dose-response\",\n      \"journal\": \"Psychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO pharmacological epistasis, single lab\",\n      \"pmids\": [\"17333137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PDE4B drives both acute local inflammatory response and chronic systemic inflammatory response after spinal cord injury; Pde4b deletion reduces markers of ER stress and inflammation at the injury site, increases oligodendrocyte mRNA expression, improves white matter sparing, and prevents SCI-induced gut dysbiosis and endotoxemia.\",\n      \"method\": \"Pde4b knockout mice, thoracic contusion SCI model, molecular markers (GFAP, CD11b, Iba1, Cox2), gut microbiome analysis, locomotor recovery assessment\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with multiple molecular and functional readouts, single lab\",\n      \"pmids\": [\"30557659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Alcohol feeding increases hepatic PDE4B expression, reduces cAMP levels, and impairs fatty acid oxidation via reduced Cpt1a expression through the Pparα/Sirt1/Pgc1α pathway; Pde4b knockout prevents alcohol-induced hepatic steatosis.\",\n      \"method\": \"Pde4b knockout mice, alcohol liquid diet feeding, hepatic cAMP measurement, gene expression analysis (Cpt1a, Pparα, Sirt1, Pgc1α), rolipram treatment\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with pharmacological validation, pathway analysis, single lab\",\n      \"pmids\": [\"27287961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PDE4B is the primary phosphodiesterase expressed in dendritic cells (DCs) and acts as a homeostatic regulator of cAMP: its expression falls when cAMP decreases and rises when cAMP increases, in a PKA-dependent feedback manner.\",\n      \"method\": \"Gαs-depleted DC mouse model, PDE4B expression analysis, PKA inhibitor experiments, PDE4B inhibitor treatment with T cell response readout\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic Gαs depletion model, pharmacological validation, single lab with multiple readouts\",\n      \"pmids\": [\"35387344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MYC and PDE4B mutually reinforce each other's expression in a feed-forward loop in B-cell lymphoma; combined targeting of Myc and PDE4 synergistically prevents B lymphoma cell proliferation and survival in vitro and in vivo.\",\n      \"method\": \"B-lymphoma cell lines, Eμ-myc transgenic mice, co-inhibition experiments, xenograft model, western blot for Myc/PDE4B expression\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic transgenic model, in vivo xenograft, multiple cell line validation; single lab\",\n      \"pmids\": [\"31138843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IL-2 activates STAT5, which binds the PDE4B gene locus to transcriptionally induce PDE4B expression in activated human PBMCs; PDE4B is expressed in CD8+ but not CD4+ primary T cells, while lymphoid cancer CD4+ cells aberrantly express PDE4B.\",\n      \"method\": \"Affymetrix microarray, ChIP-on-chip STAT5 cistrome mapping, qRT-PCR validation in PHA-activated human PBMCs, protein expression analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and gene expression validation with orthogonal methods; single lab\",\n      \"pmids\": [\"23451206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PDE4B deficiency (Pde4b-/-) prevents SCI-induced gut dysbiosis, bacterial overgrowth, and endotoxemia, suggesting PDE4B links gut-CNS inflammation after spinal cord injury.\",\n      \"method\": \"Pde4b knockout mice, thoracic contusion SCI model, gut microbiome sequencing, endotoxin measurement\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with microbiome and endotoxin readouts, single lab\",\n      \"pmids\": [\"30557659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PDE4B loss-of-function in sclera decreases cAMP and reduces collagen synthesis, leading to thinner collagen fibrils and myopia progression; inhibition of PDE4 with rolipram inhibits TGF-β2-induced collagen synthesis in human scleral fibroblasts.\",\n      \"method\": \"Pde4b knockout mice, form deprivation myopia model, scleral transcriptome sequencing, subconjunctival rolipram injection, electron microscopy of collagen fibrils, human scleral fibroblast culture\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with in vivo myopia model and in vitro fibroblast validation; single lab\",\n      \"pmids\": [\"34506801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"JDP2 (transcription factor c-Jun dimerization protein 2) directly binds the PDE4B promoter and transcriptionally activates PDE4B expression in hypoxia/reoxygenation-injured cardiomyocytes; JDP2-driven PDE4B upregulation contributes to oxidative stress and apoptosis.\",\n      \"method\": \"Dual luciferase reporter assay, chromatin immunoprecipitation, siRNA knockdown, overexpression in H9c2 cardiomyocytes under H/R conditions\",\n      \"journal\": \"Experimental and therapeutic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase reporter confirm direct transcriptional regulation; single lab\",\n      \"pmids\": [\"35401806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Acute stress reduces Pde4b-regulated cAMP signaling in auditory GABAergic neurons projecting to somatosensory cortex Sst neurons (AUDGABA-S1TrSst circuit), leading to decreased S1TrSst neuron activity and anxiety-like behavior; targeted Pde4b knockdown in S1TrSst projections mimics this anxiety.\",\n      \"method\": \"Single-cell sequencing, spatial transcriptome sequencing, targeted Pde4b protein knockdown, optogenetics/chemogenetics of S1TrSst neurons, behavioral tests\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — circuit-specific protein knockdown with behavioral and electrophysiological readouts; single lab\",\n      \"pmids\": [\"39891910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A hypomorphic PDE4B mutation (Y358C) that decreases cAMP hydrolytic activity prevents spatial memory deficits and brain metabolism impairments in the AppNL-G-F Alzheimer's disease mouse model without reducing amyloid plaque burden; transcriptomic analysis identified Ide, Btaf1, Padi2, and C1qb as differentially expressed genes relevant to this protective effect.\",\n      \"method\": \"AppNL-G-F knock-in mice crossed with Pde4bY358C hypomorphic mice, Barnes maze, 14C-2-deoxyglucose autoradiography, RNA sequencing\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic hypomorphic model with multiple functional readouts and transcriptomics; single lab\",\n      \"pmids\": [\"38521860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PDE4B missense variant M220T (rs775201287) attenuates the PDE4B1 response to forskolin-elicited cAMP elevation in HEK-293 cells, and homozygous Pde4b M220T mice show increased BDNF expression, startle hyperreactivity, PPI deficits, altered fear conditioning, and enhanced persistence of traumatic memories consistent with PTSD-relevant phenotypes.\",\n      \"method\": \"HEK-293 cell cAMP assay with PDE4B1-M220T, homozygous knock-in mice, behavioral battery, cAMP pathway analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro enzymatic function of variant plus knock-in mouse behavioral phenotyping; single lab\",\n      \"pmids\": [\"39256048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Attenuation of PDE4B1 activity (via D564A dominant-negative transgene in hippocampus/forebrain) increases CREB and ERK1/2 phosphorylation, enhances hippocampal neurogenesis, increases baseline synaptic transmission, and enhances LTP in male mice.\",\n      \"method\": \"PDE4B1-D564A dominant-negative transgenic mice, immunoblot for phospho-CREB/ERK, neurogenesis assay, hippocampal electrophysiology (LTP)\",\n      \"journal\": \"BMC neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-selective dominant-negative approach with electrophysiology and biochemical validation; single lab\",\n      \"pmids\": [\"29197324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ZNF804a directly binds chromatin proximal to the promoter regions of PRSS16 and COMT, and its expression significantly decreases PDE4B transcript levels, indicating ZNF804a transcriptionally regulates PDE4B expression.\",\n      \"method\": \"ChIP assay, ZNF804a overexpression, qRT-PCR in neural progenitor cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — ChIP shown for PRSS16/COMT but not directly for PDE4B; PDE4B regulation inferred from transcript changes without direct binding evidence\",\n      \"pmids\": [\"22384243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"During late-LTP induction in hippocampal slices, PDE4B protein changes are detected within the PSD-enriched fraction but FISH shows no translocation of PDE4B3 mRNA from soma, suggesting local post-translational modulation or protein translocation to activated synaptic structures regulates cAMP at synapses.\",\n      \"method\": \"Hippocampal slice LTP recording, subcellular fractionation, FISH, fluorescence imaging\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — fractionation with electrophysiology, single lab, mechanistic interpretation is inferential\",\n      \"pmids\": [\"15829230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NFATc2 activation is required for LPS-induced transcription of PDE4b in macrophages; PDE4b expression peaks at time of peak lung injury then falls during resolution; inhibition of PDE4 activity at peak injury increases cAMP in alveolar macrophages and augments their reparative reprogramming from recruited monocytes.\",\n      \"method\": \"RNA-seq of flow-sorted macrophages, NFATc2 inhibition assay, intratracheal rolipram, conditional monocyte depletion, adoptive transfer of rolipram-educated macrophages, LysM-GFP mice\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq, transcription factor requirement, adoptive transfer, monocyte depletion epistasis; single lab\",\n      \"pmids\": [\"34318714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PDE4B overexpression in nucleus pulposus cells upregulates ferroptosis markers (ACSL4, TFRC) and downregulates Nrf2, promoting ferroptosis and IDD pathogenesis; PDE4 inhibitor roflumilast reverses this process, with synergistic effect when combined with ferroptosis inhibitor.\",\n      \"method\": \"PDE4B overexpression in nucleus pulposus cells, in vivo rat IDD model, PDE4 inhibitor treatment, ferroptosis marker analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, overexpression/inhibitor approach, pathway inference from marker expression\",\n      \"pmids\": [\"39893206\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PDE4B is a cAMP-specific phosphodiesterase that hydrolyzes cAMP to regulate intracellular signaling: it is physically sequestered by DISC1 via the UCR2 domain in resting cells and released in an activated state upon cAMP elevation; it controls cAMP selectively in near-membrane subcellular compartments; it is transcriptionally induced by LPS (via NF-κB/PKA-Cβ cross-talk) and by IL-2/STAT5 as a feedback regulator of innate and adaptive immunity; it is degraded via Smurf2-mediated ubiquitination (protected by circDlg1); its isoform-specific activity and rolipram sensitivity are determined by alternatively spliced N-terminal regions; and it plays established roles in cardiac beta-adrenergic signaling, neuroinflammation, lymphoma survival (through a Myc-PDE4B feed-forward loop and PI3K/AKT-linked apoptosis resistance), and synaptic plasticity (LTD enhancement in hippocampus).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PDE4B is a cAMP-specific phosphodiesterase that hydrolyzes cAMP to shape spatially restricted cAMP/PKA signaling and thereby controls innate and adaptive immunity, cardiac beta-adrenergic responses, and synaptic plasticity [#5, #1, #13, #15]. Its three human splice variants differ in their unique N-terminal regions, which dictate cytosolic versus particulate distribution, maximal hydrolytic activity, and rolipram sensitivity [#2]. Functionally, PDE4B governs cAMP within a near-membrane subdomain rather than the bulk cytosol, selectively gating Toll-like receptor signaling while sparing CREB-mediated transcription [#5]. In resting cells PDE4B is sequestered through binding of its UCR2 domain to the scaffold DISC1, from which it is released and activated upon cAMP elevation; DISC1 organizes PDE4B together with NDE1, NDEL1, LIS1, and dynein at the centrosome and synapses, coupling local cAMP hydrolysis to PKA-dependent NDE1 phosphorylation [#0, #4]. Co-crystal structures define how selective inhibitors act, either by displacing the invariant Gln-443 and shifting helix-15 or by engaging a C-terminal regulatory helix (CR3) to lock the enzyme in a closed, inactive conformation [#6, #7]. In immunity, PDE4B is required for LPS-induced TNF-alpha production and is transcriptionally induced as a feedback regulator by LPS via PKA-Cbeta/NF-kappaB p65 (Ser276) cross-talk and by IL-2/STAT5, with inhibition suppressing inflammation through JNK2-dependent induction of the deubiquitinase CYLD [#1, #9, #22, #8]. PDE4B protein levels are controlled by Smurf2-mediated ubiquitination and degradation, which is blocked by the circular RNA circDlg1 acting through PDE4B's N-terminal targeting domain to maintain low cAMP and dampen anti-inflammatory PKA/CREB signaling in microglia [#10, #11]. In the heart, PDE4B blunts beta-adrenergic cAMP/PKA signaling, L-type Ca2+ current, and contraction, and protects against catecholamine- and pressure-overload-induced dysfunction, while also driving neutrophil-endothelial interactions in ischemia-reperfusion injury [#13, #12]. In B-cell lymphoma, PDE4B inactivates cAMP to abrogate apoptosis through a PKA/EPAC-independent, PI3K/AKT-linked mechanism and participates in a mutually reinforcing feed-forward loop with MYC [#3, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that PDE4B is not a single activity but a set of splice variants whose unique N-termini determine where the enzyme localizes and how it behaves enzymatically and pharmacologically.\",\n      \"evidence\": \"Cloning and expression of HSPDE4B1/2/3 in COS7 cells with fractionation, cAMP hydrolysis, and rolipram inhibition assays\",\n      \"pmids\": [\"9371714\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve isoform-specific signaling partners in vivo\", \"N-terminal targeting determinants not mapped at residue level\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Answered whether a specific PDE4 isoform controls innate immune cytokine output by showing PDE4B, not PDE4D, is required for LPS-driven TNF-alpha and is itself induced as feedback.\",\n      \"evidence\": \"PDE4B knockout mice with LPS stimulation, cytokine mRNA/protein, and PDE4 activity assays in macrophages and leukocytes\",\n      \"pmids\": [\"12032334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the transcriptional pathway inducing PDE4B\", \"Compartment of cAMP control not yet identified\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed how PDE4B promotes lymphoma survival by hydrolyzing pro-apoptotic cAMP through a PKA/EPAC-independent, PI3K/AKT-linked route.\",\n      \"evidence\": \"DLBCL cell lines reconstituted with wild-type/mutant PDE4B, cAMP-induced apoptosis assays, and constitutively active AKT epistasis\",\n      \"pmids\": [\"15331441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic link between cAMP and AKT not fully defined\", \"Did not address upstream regulation of PDE4B in lymphoma\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined the regulatory logic of PDE4B activation by showing DISC1 sequesters it via UCR2 and releases it upon cAMP elevation, coupling scaffold binding to enzyme activity.\",\n      \"evidence\": \"Co-immunoprecipitation, UCR2 domain mapping, and cellular cAMP elevation assays\",\n      \"pmids\": [\"16293762\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of UCR2-DISC1 interface not solved\", \"Did not establish physiological cAMP threshold for dissociation\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended the DISC1-PDE4B relationship into a multiprotein scaffold linking local cAMP hydrolysis to PKA phosphorylation of NDE1 at the centrosome and synapses.\",\n      \"evidence\": \"Co-immunoprecipitation and immunofluorescence in cultured neurons for DISC1/NDE1/NDEL1/LIS1/dynein/PDE4B\",\n      \"pmids\": [\"18983980\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Scaffold stoichiometry inferred, not measured\", \"Direct versus indirect interactions within the complex not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolved where PDE4B acts by demonstrating it controls cAMP in a near-membrane subdomain that selectively gates TLR signaling without affecting bulk cytosolic cAMP or CREB transcription.\",\n      \"evidence\": \"PDE4B/PDE4D gene ablation in MEFs with FRET cAMP reporters, phosphoprotein, and transcription reporter assays\",\n      \"pmids\": [\"21288894\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular anchors tethering PDE4B near the membrane not identified\", \"Did not extend compartment mapping to immune cell types\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Tied PDE4B function to synaptic plasticity and cognition by showing loss enhances hippocampal LTD and impairs reversal learning.\",\n      \"evidence\": \"PDE4B knockout mice with hippocampal slice electrophysiology and Morris water maze\",\n      \"pmids\": [\"21458469\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type and isoform responsible not dissected\", \"cAMP/PKA effectors mediating LTD change not defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed DISC1 can co-assemble PDE4B and GSK-3, and that a DISC1 variant reshapes this complex, linking genetic variation to convergent cAMP/GSK-3 signaling.\",\n      \"evidence\": \"DISC1 Q31L/L100P mutant mice with GSK-3 activity, binding assays, and rolipram/TDZD-8 pharmacological epistasis\",\n      \"pmids\": [\"21376063\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ternary complex not structurally demonstrated\", \"Functional output of converged signaling in vivo incomplete\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Provided a structural mechanism for inhibition by showing a THBT inhibitor displaces the invariant Gln-443 and shifts helix-15.\",\n      \"evidence\": \"X-ray co-crystal structure of THBT inhibitor with PDE4B\",\n      \"pmids\": [\"19525117\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish isoform selectivity in cells\", \"Conformational dynamics under physiological regulation not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined a distinct inhibitor mechanism in which triazines engage a C-terminal regulatory helix (CR3) to lock PDE4B in an inactive closed state, enabling subtype-selective design.\",\n      \"evidence\": \"High-resolution co-crystal structures with SAR analysis\",\n      \"pmids\": [\"24998378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CR3 engagement occurs with endogenous regulators unknown\", \"Selectivity over other PDE4 subtypes not validated in vivo\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Explained an anti-inflammatory mechanism of PDE4B inhibition through JNK2-selective induction of the deubiquitinase CYLD.\",\n      \"evidence\": \"PDE4 inhibitor treatment, JNK1/JNK2 selective activation, and CYLD-knockout mouse epistasis\",\n      \"pmids\": [\"23575688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Connection between cAMP and JNK2 selectivity not detailed\", \"Cell types mediating in vivo effect not fully resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified IL-2/STAT5 as a transcriptional inducer of PDE4B and revealed cell-type-restricted expression in CD8+ T cells with aberrant expression in lymphoid cancers.\",\n      \"evidence\": \"Microarray, STAT5 ChIP-on-chip, and qRT-PCR in PHA-activated human PBMCs\",\n      \"pmids\": [\"23451206\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of STAT5-driven PDE4B in T cells not tested\", \"Mechanism of aberrant CD4+ cancer expression unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established a MYC-PDE4B feed-forward loop sustaining B-lymphoma proliferation and survival, identifying a combinatorial vulnerability.\",\n      \"evidence\": \"B-lymphoma lines, Emu-myc transgenic mice, co-inhibition, and xenograft experiments\",\n      \"pmids\": [\"31138843\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional wiring between MYC and PDE4B not mapped\", \"Single-lab in vivo validation\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined a transcriptional induction mechanism for PDE4B2 via PKA-Cbeta phosphorylation of NF-kappaB p65 at Ser276, with both enzymatic and non-enzymatic contributions to chemokine induction.\",\n      \"evidence\": \"In vitro/in vivo expression, PKA-Cbeta and p65 knockdown/overexpression, Ser276 mutagenesis, and promoter assays\",\n      \"pmids\": [\"25831493\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nature of the non-enzymatic chemokine contribution unresolved\", \"Generality across stimuli beyond NTHi/roflumilast not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified Smurf2 as the E3 ligase driving ubiquitin-dependent PDE4B degradation, linking PDE4B turnover to cAMP-PKA-CREB output and downstream anti-fibrotic miR-132/CTGF signaling.\",\n      \"evidence\": \"Co-IP, transgenic overexpression/knockdown mice, miRNA array, and dual-luciferase assays\",\n      \"pmids\": [\"29100790\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination site on PDE4B not mapped\", \"Reciprocal validation of the Smurf2-PDE4B interaction limited\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed circDlg1 stabilizes PDE4B by forming a ternary complex with Smurf2 through PDE4B's N-terminal targeting domain, sustaining low cAMP and impaired anti-inflammatory PKA/CREB signaling in microglia.\",\n      \"evidence\": \"RNA pulldown/MS, RIP, Co-IP, domain mapping, and AAV knockdown in APP/PS1 mice with behavior\",\n      \"pmids\": [\"40093898\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the ternary complex not solved\", \"Single-lab in vivo validation\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated PDE4B restrains cardiac beta-adrenergic cAMP/PKA signaling and Ca2+ handling, with moderate overexpression protecting against heart failure phenotypes.\",\n      \"evidence\": \"Cardiomyocyte-specific transgenic and AAV9 PDE4B mice with FRET imaging, patch-clamp, and isoproterenol/TAC disease models\",\n      \"pmids\": [\"32264695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous PDE4B compartmentation in cardiomyocytes not fully defined\", \"Therapeutic window of overexpression not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed PDE4B drives neutrophil-endothelial interactions and microvascular dysfunction in myocardial ischemia-reperfusion via PKA-dependent adhesion molecule expression, with NO-dependent vasodilatory effects upon blockade.\",\n      \"evidence\": \"PDE4B knockout mice with bone marrow chimeras, reperfusion model, and human coronary vasomotor assays\",\n      \"pmids\": [\"35899614\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-intrinsic versus endothelial contributions only partly separated\", \"Adhesion molecule targets not exhaustively mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked PDE4B to neuroinflammation and gut-CNS crosstalk after spinal cord injury, with deletion reducing ER stress, inflammation, dysbiosis, and improving white matter sparing.\",\n      \"evidence\": \"Pde4b knockout mice with thoracic contusion SCI, molecular markers, microbiome sequencing, and locomotor recovery\",\n      \"pmids\": [\"30557659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular source of pathogenic PDE4B in cord not defined\", \"Causal direction of gut-CNS axis not fully established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established a metabolic role for PDE4B in alcohol-induced hepatic steatosis through cAMP suppression of fatty-acid oxidation via the Pparalpha/Sirt1/Pgc1alpha axis.\",\n      \"evidence\": \"Pde4b knockout mice with alcohol feeding, hepatic cAMP and gene expression analysis, and rolipram treatment\",\n      \"pmids\": [\"27287961\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PDE4B target compartment in hepatocytes not defined\", \"Isoform responsible not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed PDE4B is the dominant dendritic-cell phosphodiesterase acting as a PKA-dependent homeostatic cAMP buffer.\",\n      \"evidence\": \"Gas-depleted DC mouse model, PKA inhibitor experiments, and PDE4B inhibitor with T cell readouts\",\n      \"pmids\": [\"35387344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional mechanism of homeostatic feedback not defined\", \"Impact on antigen-specific responses limited\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified NFATc2 as a required transcription factor for LPS-induced PDE4B in macrophages and tied its temporal dynamics to lung injury and reparative reprogramming.\",\n      \"evidence\": \"RNA-seq of sorted macrophages, NFATc2 inhibition, intratracheal rolipram, monocyte depletion, and adoptive transfer\",\n      \"pmids\": [\"34318714\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct NFATc2 binding to the PDE4B locus not shown\", \"Isoform induced not specified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Mapped a circuit-level role for Pde4b in stress-induced anxiety through cAMP signaling in an auditory-to-somatosensory GABAergic projection.\",\n      \"evidence\": \"Single-cell and spatial transcriptomics, targeted Pde4b knockdown, optogenetics/chemogenetics, and behavior\",\n      \"pmids\": [\"39891910\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream cAMP effectors in the circuit not defined\", \"Isoform specificity not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided genetic evidence that reduced PDE4B activity is protective in Alzheimer's models, with a hypomorphic Y358C allele preventing memory and metabolic deficits independent of amyloid.\",\n      \"evidence\": \"AppNL-G-F mice crossed with Pde4bY358C hypomorphs, Barnes maze, deoxyglucose autoradiography, and RNA-seq\",\n      \"pmids\": [\"38521860\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking cAMP to the protective transcriptomic signature unclear\", \"Relevance of identified DEGs not functionally tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected a hypofunctional PDE4B missense variant (M220T) to PTSD-relevant behavior, linking attenuated cAMP hydrolysis to altered fear and sensorimotor gating.\",\n      \"evidence\": \"HEK-293 cAMP assays of PDE4B1-M220T and homozygous knock-in mice with behavioral battery\",\n      \"pmids\": [\"39256048\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Circuit basis of the behavioral phenotype not localized\", \"Human genetic association not established within this study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How distinct PDE4B isoforms and their N-terminal targeting determinants are matched to specific cAMP microdomains, scaffolds, and effector outputs across tissues remains incompletely defined.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified map of isoform-specific anchoring partners across cell types\", \"Endogenous structural state coupling regulation and catalysis not resolved\", \"Whether selective inhibitor conformations recapitulate physiological regulation is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [2, 5, 28]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [2, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 8, 9]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [10, 11]}\n    ],\n    \"complexes\": [\n      \"DISC1-PDE4B-NDE1-NDEL1-LIS1-dynein scaffold complex\"\n    ],\n    \"partners\": [\n      \"DISC1\",\n      \"Smurf2\",\n      \"NDE1\",\n      \"NDEL1\",\n      \"LIS1\",\n      \"GSK3\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}